IMMY曲霉半乳甘露聚糖ELISA检测血清诊断侵袭性曲霉病的性能评估
该回顾性病例对照研究评估了IMMY曲霉半乳甘露聚糖酶免疫分析法(IMMY GM-EIA)检测血清样本的性能,并确定诊断侵袭性曲霉病(IA)的最佳阳性阈值。研究纳入131例患者的175份血清样本,其中35例为可能或疑诊侵袭性真菌病(IFD)。结果显示IMMY GM-EIA与Bio-Rad GM-EIA定性一致率为94.7%(kappa=0.820);阈值≥0.5时敏感性和特异性分别为71%和98%,阈值≥0.27时分别为90%和92%。
要点
- IMMY GM-EIA与Bio-Rad GM-EIA血清检测一致性高(94.7%,kappa=0.820)。
- 阈值≥0.5时敏感性71%、特异性98%;阈值≥0.27时敏感性90%、特异性92%。
- IMMY GM-EIA可作为Bio-Rad GM-EIA的替代方法,但最佳阈值需前瞻性多中心验证。
核心结论
- IMMY GM-EIA检测血清样本的性能与Bio-Rad GM-EIA相当,可作为替代方法。
研究设计与样本
- 回顾性病例/对照研究,纳入131例患者的175份血清样本,其中35例为可能或疑诊IFD。
- 按照制造商说明进行IMMY GM-EIA检测,采用ROC分析确定最佳GMI阈值。
主要发现
- 可能IA/IFD病例(n=31)、疑诊IFD(n=4)和对照患者(n=100)的IMMY GM-EIA中位GMI分别为0.61、0.11和0.14。
- Bio-Rad GM-EIA对应的中位GMI分别为0.70、0.04和0.04。
- IMMY GM-EIA与Bio-Rad GM-EIA的总体定性样本一致率为94.7%,kappa统计量为0.820。
- GMI阳性阈值≥0.5时,IMMY GM-EIA的敏感性和特异性分别为71%和98%。
- 阈值降至≥0.27时,敏感性和特异性分别为90%和92%。
关键数值与推荐
- GMI阳性阈值≥0.5:敏感性71%,特异性98%。
- GMI阳性阈值≥0.27:敏感性90%,特异性92%。
- 与Bio-Rad GM-EIA定性一致率94.7%,kappa=0.820。
临床怎么用
- 在血清样本检测中,IMMY GM-EIA可作为Bio-Rad GM-EIA的替代方法。
- 阈值选择需权衡敏感性与特异性,≥0.27时敏感性更高但特异性略降。
局限性
- 回顾性病例/对照设计。
- 需进一步前瞻性、多中心评估以确认最佳阈值和相关临床性能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The objectives of this study were to evaluate the performance of the recently released IMMY Aspergillus galactomannan enzyme immunoassay (IMMY GM-EIA) when testing serum samples and to identify the optimal galactomannan index (GMI) positivity threshold for the diagnosis of invasive aspergillosis (IA). This was a retrospective case/control study, comprising 175 serum samples obtained from 131 patients, 35 of whom had probable or possible invasive fungal disease (IFD) as categorized using recently revised, internationally accepted definitions. The IMMY GM-EIA was performed following the manufacturer's instructions. Performance parameters were determined and receiver operator characteristic analysis was used to identify an optimal GMI threshold. Concordance with the Bio-Rad Aspergillus Ag assay (Bio Rad GM-EIA) and IMMY sona Aspergillus lateral flow assay was assessed. The median GMIs generated by the IMMY GM-EIA for samples originating from probable IA/IFD cases (n = 31), possible IFD (n = 4), and control patients (n = 100) were 0.61, 0.11, and 0.14, respectively, and were comparable to those of the Bio-Rad GM-EIA (0.70, 0.04, and 0.04, respectively). Overall qualitative observed sample agreement between the IMMY GM-EIA and Bio-Rad GM-EIA was 94.7%, generating a kappa statistic of 0.820. At a GMI positivity threshold of ≥0.5, the IMMY GM-EIA had a sensitivity and specificity of 71% and 98%, respectively. Reducing the threshold to ≥0.27 generated sensitivity and specificity of 90% and 92%, respectively. The IMMY GM-EIA provides a comparable alternative to the Bio-Rad GM-EIA when testing serum samples. Further prospective, multicenter evaluations are required to confirm the optimal threshold and associated clinical performance.
引用
- White PL, Price JS, Posso R, et al. An Evaluation of the Performance of the IMMY Aspergillus Galactomannan Enzyme-Linked Immunosorbent Assay When Testing Serum To Aid in the Diagnosis of Invasive Aspergillosis. J Clin Microbiol. 2020. PMID: 32967903. doi:10.1128/JCM.01006-20
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。